S-ICD Sales Exceeding Expectations, Boston Scientific Reports
This article was originally published in The Gray Sheet
Executive Summary
The company said when S-ICD launched that it expected the device to be a major growth driver, and that appears to be working out so far. Boston Scientific now expects the leadless implantable defibrillator to bring in $100 million in revenue this year.
You may also be interested in...
Boston Scientific Will Lean On Quadripolar, S-ICD To Revive Sagging U.S. CRM Sales
Boston Scientific reported disappointing first-quarter results for its cardiac rhythm management division, mostly due to price erosion in the U.S and the lack of a quadripolar CRT-D device. But the firm argues that the new S-ICD and forthcoming quadripolar CRT-D products may help turn the business around soon.
Subcutaneous ICD Matches Conventional Defibrillators In Registry
Boston Scientific’s S-ICD subcutaneous implantable cardioverter defibrillator performed well in the EFFORTLESS registry, with clinical event rates and inappropriate shock rates similar to those reported for conventional ICDs in a real-world context.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.